Competitive Grants Program
Pfizer supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.
Pfizer’s competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a specific area of interest and sets timelines for review and approval. Organizations are invited to submit an application addressing the specific gaps in research, practice or care as outlined in the specific RFP. The grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements.
Sign up to receive all grant announcements, including Request for Proposal (RFP) postings.
Sign Up for Alerts Details-
Title Grant Type Focus Area Country Application Due Date Real World Evidence on the Impact of Early and Appropriate Use of Aztreonam-Avibactam (ATM-AVI)Release Date:Research Inflammation & Immunology Brazil, Chile, India, Italy, South Africa, Spain, United Kingdom Guideline Concordant Care and New Data for Patients with MIBC through la/mUCEducation Oncology USA Clinical Research Studies of Atirmociclib in HR+/HER2- and/or HER2+ Breast CancerRelease Date:Research Oncology Australia, Brazil, Canada, China, France, Germany, Italy, Japan, Korea, Mexico, Spain, Taiwan, USA, United Kingdom Quality Improvement Interventions to Enhance the Care of Patients Infected by MBL-CRE or S. maltophiliaRelease Date:Quality Improvement Inflammation & Immunology Australia, Chile, India, Italy, Spain, United Kingdom Advancing Real-World Evidence in Idiopathic Inflammatory Myopathies Through a German Disease RegistryRelease Date:Research Inflammation & Immunology Germany Real-World Evidence on Clinical Outcomes with ATM-AVI in Adult Patients with Stenotrophomonas maltophilia InfectionsRelease Date:Research Inflammation & Immunology China Real-World Evidence on Clinical Outcomes with Aztreonam-Avibactam (ATM-AVI) in Adult Patients with Limited Treatment OptionsRelease Date:Research Inflammation & Immunology China Tissue Penetration and Correlation with Clinical Outcomes of ATM-AVI in Adult Patients with Limited Treatment OptionsRelease Date:Research Inflammation & Immunology China Advancing Multidisciplinary Care in HemophiliaRelease Date:Quality Improvement Rare Disease China BCMA BsAb Educational Initiatives in 2L+ Relapsed/Refractory Multiple MyelomaRelease Date:Education Oncology USA -
Title Grant Type Focus Area Country Application Due Date NSCLC Biomarker TestingRelease Date:Quality Improvement Oncology Andorra, Austria, Belgium, Canada, Denmark, Finland, France, Germany, Greece, Iceland, Ireland, Italy, Liechtenstein, Luxembourg, Malta, Monaco, Netherlands, Norway, Portugal, San Marino, Spain, Sweden, Switzerland, USA, United Kingdom Development of Talazoparib for Prostate CancerRelease Date:Partner: National Comprehensive Cancer NetworkResearch Oncology USA Approaches to Smoking Cessation CounselingRelease Date:Education Internal Medicine Australia, India, Japan, New Zealand, Singapore, Taiwan Burden of Community Acquired PneumoniaRelease Date:Research Vaccines USA Closing Knowledge Gaps in Moderate-to-Severe Alopecia AreataRelease Date:Education Inflammation & Immunology USA Progress in Androgen Deprivation Therapy (ADT) in Advanced Prostate CancerEducation Oncology USA Efforts to Promote Team-based Care and Regional Medical Collaboration for Cancer PatientsRelease Date:Partner: Japan Society of Clinical OncologyQuality Improvement Oncology Japan ISID-Pfizer 2021 Grant ChallengeRelease Date:Partner: The International Society for Infectious Diseases (ISID)Quality Improvement Hospital All Hemophilia: Improve Knowledge Level of Gene TherapyRelease Date:Education Rare Disease Japan China Medical Education in Breast Cancer Diagnosis and TreatmentRelease Date:Education Oncology China Data generation on the treatment of Metastatic Breast Cancer with CDK 4/6 inhibitorsRelease Date:Research Oncology Portugal Understanding Healthcare disparities in IBD Patients in Underserved CommunitiesRelease Date:Quality Improvement Inflammation & Immunology Canada, USA